A Phase 2 Study of Entospletinib and Decitabine Targeting
Mutant TP53 and or Complex Karyotype in Patients with
Untreated Acute Myeloid Leukemia > Age 60 years
The purpose of this study is to determine the safety and acceptability of the experimental drug, entospletinib (ENTO, GS-9973), alone and with Decitabine.
Acute Myeloid Leukemia (AML)
-Participating in the Beat AML umbrella study master protocol (reference IRB# 16475)
-Newly diagnosed with AML
-Age 60 years or older at time of diagnosis
-Has either a TP53 mutation with or without complex karyotype or Complex Karyotype without TP53 mutation
60 - n/a
Healthy Volunteers Needed
Duration of Participation
Study participation may include up to 5 years of study drug treatment and an additional 5 years after you stop taking the study drug for follow-up.
Clinical Trials Information Line
Beat AML, LLC, a division of the Leukemia and Lymphoma Society, Inc
Supported by: Gilead Pharmaceuticals